0.46 USD
▲-0.01+3.00%
盘后 0.44 -0.58%
2026-08-03
市值
$15.37M
市盈率
—
EPS
-1.57
股息率
—
52 周区间
0.28 – 2.06
成交量
125.64K
Beta
0.29
目标价
—
52W 低 0.2852W 高 2.06
价格走势
公司简介
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary scle...